This helps keep your routine consistent and avoid a long gap between your treatments
7 Cardiovascular Event Risk Reduction In patients with existing cardiovascular (CV) disease and either overweight or obesity, GLP1 receptor agonists have been approved by the U.S
Allulose is considered safe at FSA-authorised levels, though gastrointestinal side effects (bloating, diarrhoea) may occur and could be additive to GLP-1 therapy-related symptoms
They are the final layer of optimization, not the base
Timeline and What to Expect GLP-1 receptor agonists begin working at a physiological level shortly after administration, but the clinical effects patients notice develop more gradually
Blood sugar medications, beta-blockers, and levothyroxine can interfere with how semaglutide works in your body